251 related articles for article (PubMed ID: 35000271)
1. Desmoglein-3 induces YAP phosphorylation and inactivation during collective migration of oral carcinoma cells.
Ahmad US; Parkinson EK; Wan H
Mol Oncol; 2022 Apr; 16(8):1625-1649. PubMed ID: 35000271
[TBL] [Abstract][Full Text] [Related]
2. The role of YAP in the control of the metastatic potential of oral cancer.
Ahmad US; Saravanan K; Wan H
Oncol Res; 2021; 29(6):377-391. PubMed ID: 37304649
[TBL] [Abstract][Full Text] [Related]
3. YAP signaling induces PIEZO1 to promote oral squamous cell carcinoma cell proliferation.
Hasegawa K; Fujii S; Matsumoto S; Tajiri Y; Kikuchi A; Kiyoshima T
J Pathol; 2021 Jan; 253(1):80-93. PubMed ID: 32985688
[TBL] [Abstract][Full Text] [Related]
4. A YAP/TAZ-Regulated Molecular Signature Is Associated with Oral Squamous Cell Carcinoma.
Hiemer SE; Zhang L; Kartha VK; Packer TS; Almershed M; Noonan V; Kukuruzinska M; Bais MV; Monti S; Varelas X
Mol Cancer Res; 2015 Jun; 13(6):957-68. PubMed ID: 25794680
[TBL] [Abstract][Full Text] [Related]
5. Evidence for the Desmosomal Cadherin Desmoglein-3 in Regulating YAP and Phospho-YAP in Keratinocyte Responses to Mechanical Forces.
Uttagomol J; Ahmad US; Rehman A; Huang Y; Laly AC; Kang A; Soetaert J; Chance R; Teh MT; Connelly JT; Wan H
Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31835537
[TBL] [Abstract][Full Text] [Related]
6. Genome-wide CRISPR screens of oral squamous cell carcinoma reveal fitness genes in the Hippo pathway.
Chai AWY; Yee PS; Price S; Yee SM; Lee HM; Tiong VK; Gonçalves E; Behan FM; Bateson J; Gilbert J; Tan AC; McDermott U; Garnett MJ; Cheong SC
Elife; 2020 Sep; 9():. PubMed ID: 32990596
[TBL] [Abstract][Full Text] [Related]
7. Metformin inhibits mTOR and c-Myc by decreasing YAP protein expression in OSCC cells.
Wang Y; Zhang Y; Feng X; Tian H; Fu X; Gu W; Wen Y
Oncol Rep; 2021 Mar; 45(3):1249-1260. PubMed ID: 33650651
[TBL] [Abstract][Full Text] [Related]
8. The Hippo pathway transcriptional co-activator, YAP, confers resistance to cisplatin in human oral squamous cell carcinoma.
Yoshikawa K; Noguchi K; Nakano Y; Yamamura M; Takaoka K; Hashimoto-Tamaoki T; Kishimoto H
Int J Oncol; 2015; 46(6):2364-70. PubMed ID: 25846049
[TBL] [Abstract][Full Text] [Related]
9. Genomic Hippo Pathway Alterations and Persistent YAP/TAZ Activation: New Hallmarks in Head and Neck Cancer.
Faraji F; Ramirez SI; Anguiano Quiroz PY; Mendez-Molina AN; Gutkind JS
Cells; 2022 Apr; 11(8):. PubMed ID: 35456049
[TBL] [Abstract][Full Text] [Related]
10. The crosstalk between AXL and YAP promotes tumor progression through STAT3 activation in head and neck squamous cell carcinoma.
Li J; Shi C; Zhou R; Han Y; Xu S; Ma H; Zhang Z
Cancer Sci; 2020 Sep; 111(9):3222-3235. PubMed ID: 32589311
[TBL] [Abstract][Full Text] [Related]
11. Pro-invasive activity of the Hippo pathway effectors YAP and TAZ in cutaneous melanoma.
Nallet-Staub F; Marsaud V; Li L; Gilbert C; Dodier S; Bataille V; Sudol M; Herlyn M; Mauviel A
J Invest Dermatol; 2014 Jan; 134(1):123-132. PubMed ID: 23897276
[TBL] [Abstract][Full Text] [Related]
12. Molecular chaperone Hsp27 regulates the Hippo tumor suppressor pathway in cancer.
Vahid S; Thaper D; Gibson KF; Bishop JL; Zoubeidi A
Sci Rep; 2016 Aug; 6():31842. PubMed ID: 27555231
[TBL] [Abstract][Full Text] [Related]
13. Knockdown of lncRNA LEF1-AS1 inhibited the progression of oral squamous cell carcinoma (OSCC) via Hippo signaling pathway.
Zhang C; Bao C; Zhang X; Lin X; Pan D; Chen Y
Cancer Biol Ther; 2019; 20(9):1213-1222. PubMed ID: 30983488
[TBL] [Abstract][Full Text] [Related]
14. An evaluation of TAZ and YAP crosstalk with TGFβ signalling in canine osteosarcoma suggests involvement of hippo signalling in disease progression.
Luu AK; Schott CR; Jones R; Poon AC; Golding B; Hamed R; Deheshi B; Mutsaers A; Wood GA; Viloria-Petit AM
BMC Vet Res; 2018 Nov; 14(1):365. PubMed ID: 30477496
[TBL] [Abstract][Full Text] [Related]
15. The Hippo pathway effector proteins YAP and TAZ have both distinct and overlapping functions in the cell.
Plouffe SW; Lin KC; Moore JL; Tan FE; Ma S; Ye Z; Qiu Y; Ren B; Guan KL
J Biol Chem; 2018 Jul; 293(28):11230-11240. PubMed ID: 29802201
[TBL] [Abstract][Full Text] [Related]
16. EGFR Regulates the Hippo pathway by promoting the tyrosine phosphorylation of MOB1.
Ando T; Arang N; Wang Z; Costea DE; Feng X; Goto Y; Izumi H; Gilardi M; Ando K; Gutkind JS
Commun Biol; 2021 Nov; 4(1):1237. PubMed ID: 34725466
[TBL] [Abstract][Full Text] [Related]
17. TAZ target gene ITGAV regulates invasion and feeds back positively on YAP and TAZ in liver cancer cells.
Weiler SME; Lutz T; Bissinger M; Sticht C; Knaub M; Gretz N; Schirmacher P; Breuhahn K
Cancer Lett; 2020 Mar; 473():164-175. PubMed ID: 31904487
[TBL] [Abstract][Full Text] [Related]
18. Tubuloside B, a major constituent of Cistanche deserticola, inhibits migration of hepatocellular carcinoma by inhibiting Hippo-YAP pathway.
Yao J; Wan H; Zhang J; Shen W; Wei X; Shi C; Ou B; Liu D; Ge L; Fei J; Zeng X
Phytomedicine; 2024 Jul; 129():155552. PubMed ID: 38552378
[TBL] [Abstract][Full Text] [Related]
19. YAP Inhibition by Verteporfin Causes Downregulation of Desmosomal Genes and Proteins Leading to the Disintegration of Intercellular Junctions.
Huang Y; Ahmad US; Rehman A; Uttagomol J; Wan H
Life (Basel); 2022 May; 12(6):. PubMed ID: 35743822
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemistry of YAP and dNp63 and survival analysis of patients bearing precancerous lesion and oral squamous cell carcinoma.
Ono S; Nakano K; Takabatake K; Kawai H; Nagatsuka H
Int J Med Sci; 2019; 16(5):766-773. PubMed ID: 31217745
[No Abstract] [Full Text] [Related]
[Next] [New Search]
